Haemonetics Corporation (HAE)
NYSE: HAE · Surgical & Medical Instruments & Apparatus · Boston, MA
Our rating: Cautious
Call changed from Neutral to Cautious at $119.93, moderate conviction, November 6, 2026.
Breaks if: The Cautious call is wrong if Haemonetics reports organic revenue growth above 2% in each of the next two quarterly filings — at that point the top-line deterioration thesis dissolves and the FCF multiple earns a growth premium. Conversely, if the stock falls more than 20% over the next year to roughly $96 or below, the FCF yield re-rates toward 6% and the valuation objection softens considerably, warranting a reassessment toward Neutral.
Key figures
| Market value | $5.5B |
|---|---|
| Revenue, last 12 months | $1.4B |
| Net income, last 12 months | $104M |
| Free cash flow, last 12 months | $298M |
| Price to earnings | 52.7× |
| Free cash flow yield | 5.5% |
| Dividend yield | 0.0% |
| Operating margin | 12.8% |
| Return on equity | 11.9% |
| Beta to the S&P 500 | 0.50 |
| Volatility, annualized | 45.4% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 26, 2026 | $358M | 9.3% | $1.00 | $113M |
| June 27, 2026 | $339M | 5.6% | $0.72 | $44M |
| March 28, 2026 | $346M | 4.8% | $-0.41 | $53M |
| December 27, 2025 | $339M | −2.7% | $0.95 | $87M |
| September 27, 2025 | $327M | −5.3% | $0.81 | $106M |
| June 28, 2025 | $321M | −4.4% | $0.70 | $14M |
| March 29, 2025 | $331M | −3.7% | $1.17 | $101M |
| December 28, 2024 | $349M | 3.7% | $0.74 | $35M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $0.35B: Claude 62%, Gemini 90%, Mistral 82%
- Diluted earnings per share are at least $0.95: Claude 45%, Gemini 65%, Mistral 65%
- Free cash flow for the quarter is at least $0.09B: Claude 45%, Gemini 55%, Mistral 58%
- Backlog at the end of the quarter is at least $0.03B: Claude 70%, Gemini 95%, Mistral 94%
16 ledger entries and 71 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.